S&P 500 may face selling pressure as systematic funds reach full exposure
Investing.com -- Lipella Pharmaceuticals Inc (OTC:LIPO) stock plunged 23% after the clinical-stage biotechnology company was delisted from the Nasdaq Capital Market due to rule violations related to private placement transactions.
Trading in Lipella’s common stock was suspended at the market open today following the Nasdaq Hearings Panel’s determination that certain private placements completed between December 2024 and March 2025 did not comply with multiple listing rules. The panel specifically cited violations of rules concerning public interest, shareholder approval, and voting rights.
According to the company, Nasdaq identified issues with the issuance of Series C voting convertible preferred stock and warrants to Lipella’s placement agent and advisor. The transactions were deemed to be structured in a way that violated Nasdaq regulations.
Lipella expressed disappointment with the decision, noting it was "taking immediate steps to obtain stockholder approval and address the concerns raised by Nasdaq" when the delisting was announced. The company’s shares are now trading on the OTC Markets under the symbol "LIPO."
Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, stated, "We acknowledge Nasdaq’s decision and are focused on taking swift, constructive steps accordingly. Our commitment to our shareholders, our mission, and our clinical goals has not changed."
Despite the delisting, Lipella maintains that it remains "operationally sound" with intact business fundamentals. The company continues to advance its lead product candidates LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus.
The company confirmed it will continue filing periodic reports with the SEC and is "actively exploring other markets" to relist its shares on a trading venue that provides better liquidity and investor access.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.